Merck Discontinues COVID-19 Vaccine Candidates

Owing to its vaccine candidates performing poorly in its trials and not eliciting a high level of immune response against the SARS-CoV-2 virus, American pharmaceutical Merck has decided to discontinue the trials and research of two of its COVID-19 vaccine candidates. 

The company has decided to focus its attention on furthering the development of the therapeutics that they were simultaneously working on along with the vaccines.